REG - AstraZeneca PLC - Filing of Form 20-F with SEC

AstraZenecaAnnouncement

06/03/2019 07:05

RNS Number : 9502R
AstraZeneca PLC
06 March 2019
 


6 March 2019 07:00 GMT
 
FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION
 
 
AstraZeneca PLC (the Company) announced today that, on 5 March 2019, it filed its 2018 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC). The document is available for viewing on the SEC website at www.sec.gov and also on the Company's website at www.astrazeneca.com. The Company will send any holder of the Company's securities, upon request, a hard copy of the Company's complete audited financial statements free of charge. Requests may be made by writing to the Company Secretary, AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK.
 
 
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
 




Media Relations


 


 




Gonzalo Viña


UK/Global


+44 203 749 5916




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Jennifer Hursit


UK/Global


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677




 


 


 




Investor Relations


 


 




Thomas Kudsk Larsen


 


+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharma - Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


BioPharma - Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors; Corporate Access


+44 203 749 5824




US toll-free


 


+1 866 381 72 77




 


 


 




Adrian Kemp
Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRSSAESIFUSESD